CD19 and precursor B-cell acute lymphoblastic leukemia: We established a human B-ALL CD19 immune escape xenograft model using Nalm6 cells in NSG mice to assess how the therapeutic efficacy of TriBAFF/CD3/ABDCon compares with that of blinatumomab.